Concepts Inc (NASDAQ:TMCI) received an upgrade from BTIG, with analyst Ryan Zimmerman changing the stock rating from Neutral to Buy and setting a new price target of $16.00. This upgrade comes after a ...
BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from ...
In a report released yesterday, Gregory Lewis from BTIG maintained a Hold rating on Genco Shipping (GNK – Research Report). The company’s ...
Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, ...
BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...
Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note ...
What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...
In light of these considerations, Zelin updated BTIG's model to reflect a more moderate differentiation of briquilimab versus barzolvolimab and the decreased likelihood of a Q12W regimen. Despite the ...
As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback